🇺🇸 Seasonal influenza vaccine in United States
52 US adverse-event reports
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
- Window: 22 April 2025 – 22 April 2026
- Total reports: 52
Most-reported reactions
- Cough — 7 reports (13.46%)
- Dyspnoea — 6 reports (11.54%)
- Influenza — 6 reports (11.54%)
- Pneumonia — 6 reports (11.54%)
- Malaise — 5 reports (9.62%)
- Productive Cough — 5 reports (9.62%)
- Vaccination Failure — 5 reports (9.62%)
- Nasopharyngitis — 4 reports (7.69%)
- Rhinorrhoea — 4 reports (7.69%)
- Sputum Discoloured — 4 reports (7.69%)
Seasonal influenza vaccine in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Immunology approved in United States
Frequently asked questions
Is Seasonal influenza vaccine approved in United States?
Seasonal influenza vaccine does not currently have US marketing authorisation in our dataset.
Who is the marketing authorisation holder for Seasonal influenza vaccine in United States?
Novartis is the originator. The local marketing authorisation holder may differ — check the official source linked above.